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Objective. Quality of life (QOL) and quality of care (QOC) in systemic lupus erythematosus (SLE) remains poor. 
Satisfaction with care (SC), a QOC surrogate, correlates with health behaviors and outcomes. This study aimed to 
determine correlates of SC in SLE.
Methods. A total of 1262 patients with SLE were recruited from various countries. Demographics, disease activity 
(modified Systemic Lupus Erythematosus Disease Activity Index for the Safety of Estrogens in Lupus Erythematosus: 
National Assessment trial [SELENA-SLEDAI]), and QOL (LupusPRO version 1.7) were collected. SC was collected us-
ing LupusPRO version 1.7. Regression analyses were conducted using demographic, disease (duration, disease activ-
ity, damage, and medications), geographic (eg, China vs United States), and QOL factors as independent predictors.
Results. The mean (SD) age was 41.7 (13.5) years; 93% of patients were women. On the univariate analysis, age, 
ethnicity, current steroid use, disease activity, and QOL (social support, coping) were associated with SC. On the 
multivariate analysis, Asian participants had worse SC, whereas African American and Hispanic patients had better 
SC. Greater disease activity, better coping, and social support remained independent correlates of better SC. Com-
pared with US patients, patients from China and Canada had worse SC on the univariate analysis. In the multivariate 
models, Asian ethnicity remained independently associated with worse SC, even after we adjusted for geographic 
background (China). No associations between African American or Hispanic ethnicity and SC were retained when 
geographic location (Canada) was added to the multivariate model. Canadian patients had worse SC when compared 
with US patients. Higher disease activity, better social support, and coping remained associated with better SC.
Conclusion. Greater social support, coping, and, paradoxically, SLE disease activity are associated with better 
SC. Social support and coping are modifiable factors that should be addressed by the provider, especially in the 
Asian population. Therefore, evaluation of a patient’s external and internal resources using a biopsychosocial model 
is recommended. Higher disease activity correlated with better SC, suggesting that the latter may not be a good 
surrogate for QOC or health outcomes.
INTRODUCTION
Systemic lupus erythematosus (SLE) has the potential to 
interfere with many important aspects of a patient’s life, including 
their personal life as well as their physical, emotional, financial, 
and mental well-being (1). With advances in diagnosis and treat-
ment, the prognosis of SLE has significantly improved; however, 
patient-reported outcomes (PROs) indicate that patients with 
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SLE have significantly worse quality of life (QOL) compared with 
their age- and sex-matched peers. Furthermore, the cumulative 
effect of SLE on patients’ QOL may be worse than that of other 
common chronic diseases, such as congestive heart failure and 
depression (2,3).
Quality of care (QOC) and patient experience are top pri-
orities in health care, with the goal of improving QOL, which 
is considered an independent predictor of mortality in SLE (4). 
Unfortunately, QOC (evaluated as process-based care) in SLE 
is significantly lagging in several areas (5) and is tied with dam-
age accrual (6,7). Patient satisfaction with care (SC) relates to 
how well our service meets the patients’ expectations (8). SC 
is increasingly used as a surrogate for QOC because it may 
correlate with adherence, outcomes, and the patient-physician 
relationship (9–11). For example, better patient satisfaction has 
been linked to higher regimen adherence in young, mostly ethnic 
minority patients with type 1 diabetes (10). Higher SC has also 
been shown to reduce hospital readmission rates (11).
SC may be affected by factors related to patients, provid-
ers, care processes, and the disease itself (12,13). Given the 
propensity of SLE to cause a wide range of clinical manifesta-
tions with unpredictable flares (1), management can be challeng-
ing and involves collaboration between patients and their health 
care providers. There is a paucity of studies investigating SC in 
SLE. SC is associated with better health and vice versa (14,15), 
but knowledge of the factors that drive SC in SLE is still lacking.
The purpose of this study was to determine the modifiable 
and nonmodifiable correlates of SC for patients with SLE and to 
identify areas for improvement. With the results, we aim to inform 
clinicians of these correlates, recognize those at higher risk for 
poor SC, and target any modifiable variables.
PATIENTS AND METHODS
This study was approved by the site’s institutional review 
board.
Patient characteristics. Cross-sectional data were used 
from the Study of Outcomes in Lupus (SOUL) data repository. A 
total of 1262 consenting patients were recruited consecutively 
between 2009 and 2016 from multiple centers, including three 
sites in the United States as well as centers in Mexico, Argentina, 
Canada, the Philippines, Turkey, and China. All patients were 18 
years of age or older and met the American College of Rheu-
matology (ACR) 1997 revised criteria for classification of SLE 
(16,17).
Individuals completed assessments of demographics 
(age, sex, education, marital status), disease (duration), and 
PROs (LupusPROv1.7) at a single routine clinic visit. Consec-
utive patients seen in the rheumatology outpatient clinics were 
approached for participation in the LupusPRO study at each 
of the centers, and consenting patients were subsequently 
enrolled. The LupusPROv1.7 tool was validated at each of the 
participating sites for data collection. Treating rheumatologists 
provided information on comorbidities (diabetes, hypertension, 
coronary artery disease, psychiatric conditions, and fibromyal-
gia), the ACR classification criteria for SLE, current SLE medi-
cations (including steroids), disease activity (modified Systemic 
Lupus Erythematosus Disease Activity Index for the Safety of 
Estrogens in Lupus Erythematosus: National Assessment trial 
[SELENA-SLEDAI]), and damage (Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology Dam-
age Index [SDI]).
The SELENA-SLEDAI is a cumulative scoring index used 
to assess disease activity across a combination of clinical fea-
tures and laboratory test results. It is composed of 24 items with 
descriptors that must be present at the time of visit or in the 
preceding 10 days. A higher score represents greater disease 
activity (18).
The SDI is a validated tool used to quantify damage that 
has occurred since the onset of SLE and has been present for 
at least 6 months, ascertained by clinical assessment. A higher 
score indicates greater damage and has been shown to corre-
late with higher mortality (19).
LupusPROv1.7 is a disease-specific PRO questionnaire, 
comprised of 43 questions, that measures health-related qual-
ity of life (HRQOL) and non-HRQOL. Responses are ranked on 
a five-point Likert scale. The HRQOL construct includes lupus 
symptoms/flares, lupus medications, cognition, procreation, 
physical and emotional health, pain, vitality, sleep, and body 
image domains. The non-HRQOL construct includes desires/
SIGNIFICANCE & INNOVATIONS
• Social support and coping are positively correlated 
with satisfaction with care in systemic lupus erythe-
matosus (SLE). Addressing these topics could be an 
opportunity to improve patients’ satisfaction with 
care (SC), particularly among those at risk (eg, Asian 
patients), because both social support and coping 
are modifiable factors.
• Paradoxically, higher disease activity was correlat-
ed with better SC. This may reflect greater health 
care use associated with greater disease activity 
rather than quality of care or overall health out-
comes. Therefore, SC may not be a good index for 
tracking quality of care in SLE.
• Geographic factors, cultural factors, socioeconomic 
status, and health care systems may influence SC, 
besides ethnicity or race. Canadian patients had 
worse SC compared with US patients but did not 
show differences by ethnicity or race. In contrast, 
Asian patients showed worse SC, even after we 
adjusted for geographic location of Asian patients 
in China, compared with those living in the United 
States. Education, a surrogate measurement for so-
cioeconomic status, was not associated with SC.
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goals, planning, coping, social support, and SC domains. A 
higher total domain score indicates better QOL (20).
Outcome measure. SC was the primary outcome of inter-
est and was measured using the corresponding domain (“satis-
faction with care”) on LupusPROv1.7. This was assessed via four 
items: “My doctor was accessible when I had a question regard-
ing my lupus,” “My doctor understood the impact of lupus on my 
life,” “My doctor provided me with the information I needed to 
understand my lupus,” and “My doctor discussed/monitored the 
side effects of lupus medicine/s.” Each item was ranked on a five-
point Likert scale ranging from 0, indicating “none of the time,” 
to 4, denoting “all of the time.” A sixth option of “not applicable” 
was available. These were pertinent to a 3-month recall period 
(20). Because various domains of LupusPRO (including SC) may 
be correlated, for all reported analyses, we excluded SC domain 
scores from the other QOL domains on the LupusPRO.
Statistical analyses. Statistical analyses were performed 
using the IBM Statistical Package for the Social Sciences software 
(SPSS version 19; IBM Corporation). Descriptive summary statis-
tics were obtained for the group. Univariate and multivariate linear 
regressions were performed; SC was used as as the dependent 
variable, whereas patient demographic (age, sex, ethnicity, edu-
cation, comorbidities), disease (duration, disease activity, dam-
age, medications), and self-reported QOL (LupusPRO) variables 
were used as independent predictors. Education was used as a 
surrogate for socioeconomic status. Given the potential impact of 
different health care systems, culture, and socioeconomic status 
between the various countries where participants were recruited, 
we conducted a secondary analysis. We coded geographic loca-
tions for China, Canada, and the Philippines using US patients 
as a reference category and performed a univariate analysis for 
SC using geographic variables as predictor variables. Next, we 
performed the same multivariate analyses as mentioned above 
but with the addition of the geographic variable for China in model 
1 and the geographic variable for Canada in model 2 to assess for 
independent predictors (including ethnicity and country) for SC. 
R2 was used to determine the variance in SC attributed to each 
independent predictor. P ≤ 0.05 was considered significant on 
two-tailed tests.
RESULTS
Patient characteristics. Data were available for 1262 
patients with SLE. The mean (SD) age at recruitment was 41.7 
(13.5) years, and the majority (93.2%) of patients were women 
(Table 1). Ethnicities were as follows: Asian (48%), white (23%), 
Hispanic (18%), African American (10%), and other (1%). 
According to the ACR classification criteria, more than 70% of 
patients met arthritis and immunologic criteria. Hematologic 
manifestations were noted in 67% of patients; history of malar 
rash, in 56%; lupus nephritis, in 43%; and serositis, in 26%. A 
significant proportion of patients had comorbidities such as 
hypertension, psychiatric conditions, and fibromyalgia (33%, 
23.8%, and 13.7%, respectively). Less than 40% of patients were 
receiving corticosteroids. Nearly 75% of participants were on 
hydroxychloroquine at the time of the study. Azathioprine (31.3%), 
mycophenolate mofetil (14.2%), methotrexate (4.8%), and cyclo-
sporine (3.2%) were some of the other medications being used for 
SLE. The mean (SD) SELENA-SLEDAI and SDI scores were 3.47 
Table 1. Description of patients
Demographics Result
Age, mean (SD), y 41.70 (13.46)
Female sex, % 93.2
Ethnicity, %  
White 22.9
African American 9.7
Asian 48
Hispanic 17.8
Other 1.6
Education level, %  
Less than high school 20
High school 41.7
College or university degree 30.5
Graduate degree or higher 7.7
Medications, %  
Currently using steroids 37.3
Ever used steroids 74.2
Hydroxychloroquine 62.6
Methotrexate 4.8
Azathioprine 31.3
Mycophenolate 14.2
Cyclophosphamide 0.9
Cyclosporine 3.2
Comorbidities, %  
Diabetes mellitus 5
Hypertension 33
Coronary artery disease 4.8
Psychiatric condition, including depression 23.8
Fibromyalgia 13.7
ACR criteria, %  
Malar rash 55.9
Discoid rash 15.7
Photosensitivity 49.3
Oral or nasal sores 31.2
Arthritis 73.2
Serositis 26.1
Renal disorder 42.8
Neurology disorder 9.4
Hematology disorder 67.1
Positive immunology 78.8
Positive ANA antibodies 98.6
Disease severity  
PGA, mean (SD) 0.75(0.83)
Total SELENA-SLEDAI score 3.47(4.12)
Total SDI score 0.90(1.49)
Abbreviation: ACR, American College of Rheumatology; ANA, anti-
nuclear; PGA, Physician Global Assessment; SDI, Systemic Lupus In-
ternational Collaborating Clinics/American College of Rheumatology 
Damage Index; SELENA-SLEDAI, modified Systemic Lupus Erythema-
tosus Disease Activity Index for the Safety of Estrogens in Lupus Ery-
thematosus: National Assessment trial.
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(4.12) and 0.90 (0.49), respectively. Summary scores are shown 
in Table 1.
SC and QOL. The mean (SD) SC was 64.02 (33.54), and 63% 
to 66% of patients responded favorably (“most” or “all of the time”) 
to each of the four SC domain items. The distribution of LupusPRO 
scores (mean [SD]) on other domains is shown in Figure 1.
Correlates of SC. By using the univariate linear regres-
sion analyses, greater age was associated with worse SC. 
Education, a surrogate for socioeconomic status, and sex 
were not associated with SC. Asian patients had worse SC, 
whereas African American patients had better SC. Disease 
duration and damage did not correlate with SC, but current 
steroid use was associated with worse SC. Contrary to our 
expectation, greater disease activity and worse functioning of 
desires/goals on the QOL domain were associated with bet-
ter SC. Better social support and coping on the QOL domain 
correlated with better SC (Table 2). Of all the variables, most 
variability in SC was explained by coping (R2 0.20) and social 
support (R2 0.14).
On the multivariate regression analysis, independent predic-
tors of SC were ethnicity, disease activity, and QOL. Directions of 
these correlations were the same as those in the univariate analy-
sis. Age and current steroid use did not retain association with SC 
in this multivariate model (Table 2). Collectively, these accounted 
for 30% of variability in SC.
In our secondary analysis, US patients fared better than 
non-US patients on SC in the univariate analysis (β 0.34; 95% 
confidence interval [CI] 21.19-28.94; P < 0.001; R2 0.12). 
Patients from China (β −0.53; 95% CI −39.44 to −31.72; P 
< 0.001; R2 0.29) and Canada (β −0.28; 95% CI −24.62 to 
Figure 1. Quality of Life (including satisfaction with care) by using LupusPRO.
Table 2. Predictors of satisfaction with care
Variable
Univariate Analyses Multivariate Analyses
R2 β 95% CI P R2 β 95% CI P
Age 0.005 −0.07 −0.31 to −0.03 0.018 0.30 −0.008 −0.15 to −0.11 0.772
Ethnicity or racea         
African American 0.01 0.1 5.11 to 17.99 <0.001 0.30 0.06 0.55 to 16.70 0.036
Asian 0.08 −0.28 −22.32 to −15.14 <0.001 0.30 −0.12 −11.81 to −3.58 <0.001
Hispanic 0.08 0.28 20.05 to 29.44 <0.001 0.30 0.18 10.61 to 21.27 <0.001
Disease features         
Steroid use currently 0.02 −0.13 −12.42 to −4.77 <0.001 0.30 −0.034 −5.71 to 1.13 0.19
Total SLEDAI score 0.02 0.15 0.72 to 1.65 <0.001 0.30 0.09 0.35 to 1.18 <0.001
QOL         
LupusPRO-COG 0.004 0.06 0.01 to 0.15 0.028 0.30 0.03 −0.03 to 0.11 0.27
LupusPRO-DG 0.01 −0.12 −0.22 to −0.08 <0.001 0.30 −0.09 −0.19 to −0.05 0.001
LupusPRO-SS 0.14 0.37 0.33 to 0.43 <0.001 0.30 0.14 0.08 to 0.20 <0.001
LupusPRO-CO 0.20 0.44 0.49 to 0.62 <0.001 0.30 0.29 0.29 to 0.44 <0.001
Abbreviation: CI, confidence interval; CO, Coping; COG, Cognition; DG, Desires-Goals; QOL, quality of life; SLEDAI, Systemic Lupus Erythematosus 
Disease Activity Index; SS, Social Support.
aOther ethnicity or race as a reference. 
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−13.86; P < 0.001; R2 0.08) fared worse on SC compared 
with US patients in the univariate analysis. When we per-
formed the multivariate analysis (as in Table 2) using an addi-
tional variable for geographic location for China (model 1) 
and Canada (model 2) (Table  3), Asian ethnicity remained a 
significant independent inverse predictor of SC, whereas the 
geographic variable for China and disease activity did not. In 
model 1, the only independent predictors for SC were Asian 
ethnicity, social support, and coping. The whole model (model 
1) explained 41% of variance of SC. In model 2, with the addi-
tion of the geographic variable for Canada, the only significant 
independent predictors for SC that remained were disease 
activity, social support, coping, and the geographic location. 
Canadian patients had worse SC compared with US patients 
after we accounted for age, ethnicity, disease activity, steroid 
use, and QOL. Collectively, model 2 explained 48% variance 
in SC (Table 3).
DISCUSSION
Improving QOC and patient experience remains one of 
the top priorities in health care despite being a challenging 
task for both physicians and health care administrators. This 
is especially important in SLE because the disease has mul-
tiple manifestations, is associated with significant diagnostic 
delays, and lacks effective yet safe treatment options. Further-
more, SLE requires long-term, comprehensive care, which is 
often multidisciplinary.
QOC may be judged in various ways. These may include 
patients’ evaluation of access to care, efficiencies and safety 
of health care processes, quality of patient-physician interac-
tions, and health care facility, among others. QOC may also 
be inferred by the physician meeting certain standard-of-care 
metrics or by tracking patients’ health outcomes (eg, remis-
sion, flares, morbidity, and mortality). Health care centers and 
third parties may judge QOC by balancing services provided 
against metrics of avoidable urgent and emergent health care 
use by the patients.
QOC in SLE is suboptimal, and poor QOC may lead to 
irreversible damage (6,7). SC is one way to judge QOC, and 
it may influence patients’ adherence to treatment, patient- 
physician relationships, and health outcomes (eg, number of 
medications, flares, and hospitalizations) (21–24). Health care 
services routinely track patients’ SC with individual physicians, 
practices, and hospitals (eg, Press Ganey scores) (25). We 
undertook the study to enhance our understanding of SC and, 
specifically, its drivers because the health status of patients 
with SLE may be improved by increasing patients’ social sup-
port and SC (14).
Little is known about SC in SLE. Our overall understand-
ing of SC relies on data from the general inpatient setting 
or secondary care interface. The studies pertaining to SC in 
SLE are focused more on treatment satisfaction rather than 
exploring other facets that may contribute to SC, such as psy-
chosocial factors, coping strategies, and the patient-provider 
relationship (26,27). One of the main reasons cited by patients 
with SLE for treatment adherence is trust in their rheumatol-
ogist, whereas the reason for nonadherence originates from 
difficulty in accepting a chronic disease diagnosis that requires 
lifelong therapy (28). Both of these factors may be related to 
the QOC provided, and thereby, patients’ SC. Internal and 
external resources available to the patient (eg, social support 
Table 3. Secondary analyses for SC with geographic region
Variable
Multiple Regression Models
Model 1 (China vs United States) Model 2 (Canada vs United States)
R2 β 95% CI P R2 β 95% CI P
Age 0.41 0.05 −0.03 to 0.27 0.120 0.48 −0.003 −0.22 to 0.21 0.95
Ethnicity or racea         
African American 0.41 −0.01 −17.33 to 13.28 0.800 0.48 0.02 −8.33 to 12.82 0.68
Asian 0.41 −0.77 −89.12 to −15.12 0.006 0.48 0.04 −6.14 to 15.94 0.38
Hispanic 0.41 −0.02 −15.16 to 11.61 0.800 0.48 0.03 −9.92 to 14.16 0.73
Disease features         
Steroid use currently 0.41 0.03 −2.18 to 5.78 0.380 0.48 0.04 −3.74 to 8.75 0.43
Total SLEDAI score 0.41 0.03 −0.30 to 0.82 0.370 0.48 0.10 0.15 to 1.56 0.02
QOL         
LupusPRO-COG 0.41 −0.01 −0.09 to 0.07 0.750 0.48 0.02 −0.09 to 0.14 0.66
LupusPRO-DG 0.41 −0.02 −0.10 to 0.06 0.560 0.48 −0.07 −0.20 to 0.03 0.15
LupusPRO-SS 0.41 0.18 0.11 to 0.26 <0.001 0.48 0.17 0.07 to 0.26 0.001
LupusPRO-CO 0.41 0.17 0.12 to 0.30 <0.001 0.48 0.22 0.16 to 0.41 <0.001
Geographic regionb 0.41 0.26 −17.53 to 52.36 0.33 0.48 −0.22 −25.68 to −3.49 0.01
Abbreviation: CI, confidence interval; CO, Coping; COG, Cognition; DG, Desires-Goals; QOL, quality of life; SC, satisfaction with care; SLEDAI, 
Systemic Lupus Erythematosus Disease Activity Index; SS, Social Support.
aOther ethnicity or race as a reference. 
bUnited States as a reference. 
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and coping) may also influence patients’ understanding and 
acceptance of the diagnosis as well as impact management 
and shared decision-making.
Both social support and coping were independently associ-
ated with better SC. Because both social support and coping are 
modifiable factors, we suggest evaluation of these QOL domains 
in all patients SLE by using comprehensive, disease-specific PRO 
tools, such as LupusPRO. In fact, it has been found that better 
self-reported physical and mental health status and social support 
are associated with higher patient satisfaction among patients 
with SLE (14). Patients with SLE with poorer social networks may 
have greater unmet needs, which consequently reflects onto their 
health care needs and increases their satisfaction threshold. Alter-
natively, patients with better social support may be equipped with 
the skills needed to ensure that their health care expectations are 
met and, hence, are more likely to be satisfied (29). Similarly, social 
support as a correlate of SC has been previously reported in fibro-
myalgia and other diseases (30). Because one-third of patients 
with SLE may have fibromyalgia, social support may be of addi-
tional relevance.
Because SLE commonly affects younger patients, it poses 
unique challenges, including coping with a diagnosis of chronic 
disease, need for lifelong medical care, unpredictable flares, organ 
damage, changes in body function, functional abilities, appear-
ance, poor external or internal reserves (financial and social 
resources), and disruptions in normative milestones (eg, vocation, 
dating, pregnancy, parenting). Stress is known to contribute to 
systemic inflammation and flares in autoimmune diseases. With-
out access to appropriate coping resources, patients may resort 
to maladaptive coping techniques. Resilience, catastrophizing, 
and helplessness are known predictors of health outcomes in SLE 
(31–33). Coping, a modifiable driver for SC, may be overlooked by 
health professionals (34). We recommend integration of a biopsy-
chosocial model of health care for SLE, whereby patients’ external 
and internal resources (social support and coping) are evaluated, 
and appropriate referrals and resources are provided to address 
these issues. Interventions may include offering educational mate-
rials to patients and their caregivers and incorporating social work 
services.
Disparities in health care access and outcomes arising from 
socioeconomic status and ethnicity remain a predicament. SLE has 
a higher prevalence in ethnic minorities and demonstrates worse 
outcomes. It is difficult to distinguish whether this discrepancy 
exists because of variability in the lupus phenotype among differ-
ent ethnicities versus a consequence of different health behaviors, 
communication barriers (35), access to care, and socioeconomic 
status. In this study, we did not find an association between SC and 
education, which was used as a surrogate for socioeconomic sta-
tus. However, we found a significant association between patients’ 
ethnicity and SC. African American and Hispanic patients reported 
better SC, whereas Asian patients reported worse SC. This may be 
explained by an imbalance in expectations and appraisal between 
various ethnic groups (36). Negative evaluations of care may also 
stem from communication issues between patients of the ethnic 
minority and their health care providers. These communication 
exchanges may be challenging to both parties and, for the patient, 
may be built on past negative experiences involving miscommuni-
cation, disrespect, or lack of trust.
Because health care systems may differ across various geo-
graphic areas, it may confound the relationship between ethnicity 
and SC. We did note differential SC across US patients compared 
with non-US patients and among Chinese and Canadian patients 
compared with US patients. When accounting for the geographic 
location (China vs United States), we still found Asian ethnicity to 
be associated with worse SC. This finding suggests that health 
behaviors, cultural beliefs (8), appraisal, and different expectations 
may play a role within the Asian population rather than a difference 
in health care systems and delivery. Such an association with eth-
nicity and SC was not noted among patients in Canada versus 
the United States when geographic location was explored. It is 
known that expenditure for care is significantly higher for patients 
with SLE in the United States compared with Canada, without sig-
nificant gains in health outcomes. In the Tri-Nation study, patients 
with SLE from Canada had better health status compared with US 
patients, and no significant differences in patient satisfaction were 
noted (37). These issues need to be further studied.
Another modifiable variable is disease activity. Hypothetically, 
one would expect patients with low disease activity or in remission 
to have better SC because disease activity is linked with damage 
accrual, hospitalization, QOL, and mortality. The use of a stand-
ardized disease activity measurement as a surrogate for QOC 
would thus be justifiable. Paradoxically, we found greater disease 
activity to be associated with better SC. This could be potentially 
due to greater health care use and frequent interactions with the 
health care providers given the acuity or flare activity. In a nationally 
representative cohort, higher patient satisfaction was associated 
with greater inpatient use and higher overall health care and pre-
scription drug expenditures. Greater satisfaction was also asso-
ciated with greater mortality (38). As a result, patient satisfaction 
surveys (eg, Press Ganey scores) may not be a good outcome 
to track as a surrogate for QOC. This may especially be true dur-
ing acute health episodes when a patient’s expectations may be 
directed at short-term gains such as reversibility, stabilization of 
acute health issues, discharge to home, and immediate survival.
There are several limitations to our study. First and fore-
most, we used existent data on four items of the SC LupusPRO 
domain to estimate SC. This was a limited scope to assess 
SC. Use of other comprehensive measurement tools for SC 
would have been ideal. Previously used SC tools are the Treat-
ment Satisfaction Questionnaire for Medication (39) and the 
Treatment Satisfaction with Medicines Questionnaire (40). More 
recently, the Lupus Satisfaction Questionnaire was developed 
to comprehensively measure treatment satisfaction specifically 
in lupus (27). The second limitation was the cross-sectional 
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design, which could only suggest associations and not cau-
sality. Thirdly, SC is affected by many confounders and modifi-
ers, such as socioeconomic status, education, access to care, 
cultural and health beliefs, health behaviors, and health care 
systems. Education was used as a singular surrogate for socio-
economic status. We did not take into account other variables, 
such as income or health insurance, to measure socioeco-
nomic status, which might have contributed to a lack of asso-
ciation. Although we tried to undertake a secondary analysis by 
adjusting for the geographic location of patients, it is possible 
that differences attributed to ethnicity or geographic regions 
were due to other factors not studied. Lastly, we had a greater 
representation of Asian patients and lower disease activity and 
damage, which limits the generalizability. Studies that include 
a more comprehensive evaluation of SC in SLE are indicated.
Our study has several strengths. These include a large, 
ethnically diverse, international patient cohort that provides gen-
eralizability and confidence in the main findings. The analyses 
were adjusted for age, ethnicity, steroid use, disease activity, and 
QOL. This is the first study to investigate the drivers of SC using 
a disease-specific tool (LupusPROv1.7) to measure QOL and 
SC. The tool has also been previously validated in these various 
patient groups, languages, and countries (20).
In conclusion, social support and coping are major inde-
pendent and modifiable determinants of SC. Our results 
emphasize the need to use comprehensive PRO tools (such 
as LupusPRO) that evaluate social support, coping, and SC 
during routine medical care visits. It is also important to spe-
cifically address these modifiable variables in high-risk patients 
(eg, Asian patients) by using a biopsychosocial model of care for 
chronic diseases to improve overall outcomes. Lastly, our study 
suggests that SC may not be a good QOC surrogate to follow in 
patients with active SLE.
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